ArticleClinical chemistry2011
Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity.
Article in Clinical chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Review
- Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases.Frontiers in chemistry · 2021Review
- Biochemically Tracked Variability of Blood Plasma Thawed-State Exposure Times in a Multisite Collection Study.Biopreservation and biobanking · 2020Article
- Maillard Proteomics: Opening New Pages.International journal of molecular sciences · 2017Review
- Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms.Proteomes · 2016Review
- Transition from identity to bioactivity-guided proteomics for biomarker discovery with focus on the PF2D platform.Proteomics. Clinical applications · 2016Review
- Unexpected crosslinking and diglycation as advanced glycation end-products from glyoxal.Journal of the American Society for Mass Spectrometry · 2014Article
- Elevated plasma albumin and apolipoprotein A-I oxidation under suboptimal specimen storage conditions.Molecular & cellular proteomics : MCP · 2014Article
- Review
- Top-down proteomics of a drop of blood for diabetes monitoring.Journal of proteome research · 2014Article
- Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases.PloS one · 2014Article
- Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes.Proteomics. Clinical applications · 2013Review
- Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.Clinical biochemistry · 2013Article
- The emergence of top-down proteomics in clinical research.Genome medicine · 2013Article
- Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MS.Bioanalysis · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIn 2008, the US Food and Drug Administration (FDA) issued a Guidance for Industry statement formally recognizing (during drug development) the conjoined nature of type 2 diabetes (T2D) and cardiovascular disease (CVD), which has precipitated an urgent need for panels of markers (and means of analysis) that are able to differentiate subtypes of CVD in the context of T2D. Here, we explore the possibility of creating such panels using the working hypothesis that proteins, in addition to carrying time-cumulative marks of hyperglycemia (e.g., protein glycation in the form of Hb A(₁c)), may carry analogous information with regard to systemic oxidative stress and aberrant enzymatic signaling related to underlying pathobiologies involved in T2D and/or CVD.
methodsWe used mass spectrometric immunoassay to quantify, in targeted fashion, relative differences in the glycation, oxidation, and truncation of 11 specific proteins.
resultsProtein oxidation and truncation (owing to modified enzymatic activity) are able to distinguish between subsets of diabetic patients with or without a history of myocardial infarction and/or congestive heart failure where markers of glycation alone cannot.
conclusionMarkers based on protein modifications aligned with the known pathobiologies of T2D represent a reservoir of potential cardiovascular markers that are needed to develop the next generation of antidiabetes medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.